DARE Daré Bioscience | $0.35
+3.0% | 1/30/2024 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of Daré Bioscience (NASDAQ:DARE) on 1/30/2024 |
BYRN Byrna Technologies | $8.89
+8.2% | 9/27/2023 | Downgraded by | Dawson James | - | Buy -> Neutral | | Low | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 9/27/2023 |
BYRN Byrna Technologies | $8.89
+8.2% | 7/12/2023 | Target Lowered by | Dawson James | - | | $9.50 -> $7.25 | Low | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 7/12/2023 |
TOON Kartoon Studios | $1.26
+0.8% | 7/11/2023 | Target Lowered by | Dawson James | - | | $12.50 -> $10.00 | Low | View details for Dawson James rating of Kartoon Studios (NASDAQ:TOON) on 7/11/2023 |
NRXP NRx Pharmaceuticals | $0.46
+14.9% | 3/17/2023 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | | Low | View details for Dawson James rating of NRx Pharmaceuticals (NASDAQ:NRXP) on 3/17/2023 |
SMSI Smith Micro Software | $0.81
-1.2% | 2/28/2023 | Target Lowered by | Dawson James | - | | $8.30 -> $3.50 | Low | View details for Dawson James rating of Smith Micro Software (NASDAQ:SMSI) on 2/28/2023 |
|
SRNE Sorrento Therapeutics | $0.04
+114.3% | 2/13/2023 | Downgraded by | Dawson James | - | Buy -> Neutral | | N/A | View details for Dawson James rating of Sorrento Therapeutics (NASDAQ:SRNE) on 2/13/2023 |
ZOM Zomedica | $0.13
| 1/6/2023 | Initiated by | Dawson James | Analyst J. Kolbert | Buy | $6.00 | N/A | View details for Dawson James rating of Zomedica (NYSEAMERICAN:ZOM) on 1/6/2023 |
BYRN Byrna Technologies | $8.89
+8.2% | 9/8/2022 | Target Lowered by | Dawson James | - | | $12.00 -> $9.50 | Low | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 9/8/2022 |
PRPH ProPhase Labs | $5.25
+1.0% | 7/21/2022 | Downgraded by | Dawson James | - | Neutral -> Sell | | Low | View details for Dawson James rating of ProPhase Labs (NASDAQ:PRPH) on 7/21/2022 |
DYAI Dyadic International | $1.38
-3.5% | 7/18/2022 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of Dyadic International (NASDAQ:DYAI) on 7/18/2022 |
BYRN Byrna Technologies | $8.89
+8.2% | 4/26/2022 | Initiated by | Dawson James | - | Buy | $12.00 | High | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 4/26/2022 |
LCTX Lineage Cell Therapeutics | $1.08
+2.9% | 3/11/2022 | Reiterated by | Dawson James | Analyst Jason Kolbert | Buy | $6.00 | N/A | View details for Dawson James rating of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) on 3/11/2022 |
SMSI Smith Micro Software | $0.81
-1.2% | 3/11/2022 | Target Lowered by | Dawson James | - | Buy | $11.40 -> $8.30 | High | View details for Dawson James rating of Smith Micro Software (NASDAQ:SMSI) on 3/11/2022 |
PFIE Profire Energy | $1.46
-0.7% | 3/9/2022 | Target Raised by | Dawson James | - | | $1.65 -> $2.00 | Low | View details for Dawson James rating of Profire Energy (NASDAQ:PFIE) on 3/9/2022 |
KNWN Know Labs | $0.48
-2.0% | 2/8/2022 | Initiated by | Dawson James | - | Buy | $7.00 | High | View details for Dawson James rating of Know Labs (OTCMKTS:KNWN) on 2/8/2022 |
BCLI Brainstorm Cell Therapeutics | $0.39
+2.6% | 12/22/2021 | Reiterated by | Dawson James | Analyst J. Kolbert | Neutral | | Medium | View details for Dawson James rating of Brainstorm Cell Therapeutics (NASDAQ:BCLI) on 12/22/2021 |
VUZI Vuzix | $1.69
+0.6% | 12/21/2021 | Initiated by | Dawson James | - | Buy | $15.00 | Medium | View details for Dawson James rating of Vuzix (NASDAQ:VUZI) on 12/21/2021 |
PRPH ProPhase Labs | $5.25
+1.0% | 10/13/2021 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Medium | View details for Dawson James rating of ProPhase Labs (NASDAQ:PRPH) on 10/13/2021 |
PFIE Profire Energy | $1.46
-0.7% | 8/5/2021 | Initiated by | Dawson James | Analyst James McIlree | Buy | $1.65 | High | View details for Dawson James rating of Profire Energy (NASDAQ:PFIE) on 8/5/2021 |
SMSI Smith Micro Software | $0.81
-1.2% | 8/5/2021 | Initiated by | Dawson James | - | Buy | $11.10 | High | View details for Dawson James rating of Smith Micro Software (NASDAQ:SMSI) on 8/5/2021 |
AVXL Anavex Life Sciences | $5.69
+1.8% | 6/21/2021 | Target Raised by | Dawson James | - | Buy | $19.00 -> $35.00 | Low | View details for Dawson James rating of Anavex Life Sciences (NASDAQ:AVXL) on 6/21/2021 |
CTXR Citius Pharmaceuticals | $0.61
| 2/25/2021 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | $6.00 | Low | View details for Dawson James rating of Citius Pharmaceuticals (NASDAQ:CTXR) on 2/25/2021 |
FBIO Fortress Biotech | $1.80
+2.9% | 2/17/2021 | Target Raised by | Dawson James | - | Buy | $240.00 -> $315.00 | Low | View details for Dawson James rating of Fortress Biotech (NASDAQ:FBIO) on 2/17/2021 |
PRPH ProPhase Labs | $5.25
+1.0% | 1/20/2021 | Initiated by | Dawson James | - | Buy | $25.00 | High | View details for Dawson James rating of ProPhase Labs (NASDAQ:PRPH) on 1/20/2021 |
LCTX Lineage Cell Therapeutics | $1.08
+2.9% | 10/12/2020 | Reiterated by | Dawson James | - | Buy | $6.00 | N/A | View details for Dawson James rating of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) on 10/12/2020 |
CTXR Citius Pharmaceuticals | $0.61
| 9/17/2020 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | | Low | View details for Dawson James rating of Citius Pharmaceuticals (NASDAQ:CTXR) on 9/17/2020 |
DARE Daré Bioscience | $0.35
+3.0% | 7/12/2020 | Reiterated by | Dawson James | - | Buy | $3.00 | High | View details for Dawson James rating of Daré Bioscience (NASDAQ:DARE) on 7/12/2020 |
AVXL Anavex Life Sciences | $5.69
+1.8% | 6/8/2020 | Reiterated by | Dawson James | - | Buy | $16.00 | Medium | View details for Dawson James rating of Anavex Life Sciences (NASDAQ:AVXL) on 6/8/2020 |
SRNE Sorrento Therapeutics | $0.04
+114.3% | 5/26/2020 | Initiated by | Dawson James | - | Buy -> Buy | $24.00 | Low | View details for Dawson James rating of Sorrento Therapeutics (NASDAQ:SRNE) on 5/26/2020 |
CTSO Cytosorbents | $1.02
| 3/9/2020 | Reiterated by | Dawson James | - | Buy | $15.00 -> $17.00 | High | View details for Dawson James rating of Cytosorbents (NASDAQ:CTSO) on 3/9/2020 |
DYAI Dyadic International | $1.38
-3.5% | 2/26/2020 | Reiterated by | Dawson James | Analyst Jason Kolbert | Buy | | High | View details for Dawson James rating of Dyadic International (NASDAQ:DYAI) on 2/26/2020 |
IMAC IMAC | $2.05
+2.5% | 1/14/2020 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of IMAC (NASDAQ:IMAC) on 1/14/2020 |
MESO Mesoblast | $1.82
+1.7% | 12/19/2019 | Initiated by | Dawson James | Analyst Jason Kolbert | Buy | $28.00 | Low | View details for Dawson James rating of Mesoblast (NASDAQ:MESO) on 12/19/2019 |
DYAI Dyadic International | $1.38
-3.5% | 10/16/2019 | Initiated by | Dawson James | - | Buy | $14.00 | Low | View details for Dawson James rating of Dyadic International (NASDAQ:DYAI) on 10/16/2019 |
CTXR Citius Pharmaceuticals | $0.61
| 9/6/2019 | Initiated by | Dawson James | Analyst Jason Kolbert | Buy | $7.00 | N/A | View details for Dawson James rating of Citius Pharmaceuticals (NASDAQ:CTXR) on 9/6/2019 |
FBIO Fortress Biotech | $1.80
+2.9% | 8/26/2019 | Initiated by | Dawson James | - | Buy | $285.00 | High | View details for Dawson James rating of Fortress Biotech (NASDAQ:FBIO) on 8/26/2019 |
ADMA ADMA Biologics | $5.17
-0.2% | 8/12/2019 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | $4.00 | High | View details for Dawson James rating of ADMA Biologics (NASDAQ:ADMA) on 8/12/2019 |
AVXL Anavex Life Sciences | $5.69
+1.8% | 7/24/2019 | Initiated by | Dawson James | Analyst J. Kolbert | Buy | $16.00 | Low | View details for Dawson James rating of Anavex Life Sciences (NASDAQ:AVXL) on 7/24/2019 |
INTT inTEST | $11.65
+3.9% | 12/28/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | High | View details for Dawson James rating of inTEST (NYSE:INTT) on 12/28/2018 |
|
SSNT SilverSun Technologies | $13.37
+2.1% | 12/19/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | High | View details for Dawson James rating of SilverSun Technologies (NASDAQ:SSNT) on 12/19/2018 |
BCLI Brainstorm Cell Therapeutics | $0.39
+2.6% | 12/18/2018 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | | High | View details for Dawson James rating of Brainstorm Cell Therapeutics (NASDAQ:BCLI) on 12/18/2018 |
WYY WidePoint | $2.95
+6.5% | 12/3/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | High | View details for Dawson James rating of WidePoint (NYSEAMERICAN:WYY) on 12/3/2018 |
WTT Wireless Telecom Group | $2.13
| 12/3/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | Low | View details for Dawson James rating of Wireless Telecom Group (NYSEAMERICAN:WTT) on 12/3/2018 |
CNVS Cineverse | $1.43
-0.7% | 10/22/2018 | Initiated by | Dawson James | Analyst B. Sine | Buy | | Low | View details for Dawson James rating of Cineverse (NASDAQ:CNVS) on 10/22/2018 |
FRX Fennec Pharmaceuticals | C$13.40
+0.5% | 10/10/2018 | Reiterated by | Dawson James | Analyst C. Werther | Buy | | N/A | View details for Dawson James rating of Fennec Pharmaceuticals (TSE:FRX) on 10/10/2018 |
FENC Fennec Pharmaceuticals | $10.13
+1.1% | 10/11/2018 | Initiated by | Dawson James | Analyst C. Werther | Buy | | High | View details for Dawson James rating of Fennec Pharmaceuticals (NASDAQ:FENC) on 10/11/2018 |
LUNA Luna Innovations | $7.50
+0.5% | 10/2/2018 | Initiated by | Dawson James | Analyst B. Sine | Buy | | Low | View details for Dawson James rating of Luna Innovations (NASDAQ:LUNA) on 10/2/2018 |
SSKN STRATA Skin Sciences | $0.54
| 9/4/2018 | Initiated by | Dawson James | Analyst R. Wasserman | Buy | | High | View details for Dawson James rating of STRATA Skin Sciences (NASDAQ:SSKN) on 9/4/2018 |
VERU Veru | $0.41
-6.8% | 6/25/2018 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | Medium | View details for Dawson James rating of Veru (NASDAQ:VERU) on 6/25/2018 |
LVO LiveOne | $1.49
+1.4% | 6/4/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | Medium | View details for Dawson James rating of LiveOne (NASDAQ:LVO) on 6/4/2018 |
ALT Altimmune | $9.69
-6.4% | 5/29/2018 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | High | View details for Dawson James rating of Altimmune (NASDAQ:ALT) on 5/29/2018 |
ACST Acasti Pharma | $2.45
+3.8% | 1/29/2018 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | Low | View details for Dawson James rating of Acasti Pharma (NASDAQ:ACST) on 1/29/2018 |
CVM CEL-SCI | $2.83
-1.0% | 10/16/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Neutral | | N/A | View details for Dawson James rating of CEL-SCI (NYSE:CVM) on 10/16/2017 |
PAVM PAVmed | $1.68
-3.4% | 9/5/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | $151.50 | High | View details for Dawson James rating of PAVmed (NASDAQ:PAVM) on 9/5/2017 |
EPIX ESSA Pharma | $10.45
-1.9% | 8/3/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | High | View details for Dawson James rating of ESSA Pharma (NASDAQ:EPIX) on 8/3/2017 |
ONTX Onconova Therapeutics | $0.68
| 7/25/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | High | View details for Dawson James rating of Onconova Therapeutics (NASDAQ:ONTX) on 7/25/2017 |
CVM CEL-SCI | $2.83
-1.0% | 3/11/2016 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | N/A | View details for Dawson James rating of CEL-SCI (NYSE:CVM) on 3/11/2016 |
ENZ Enzo Biochem | $1.35
+6.3% | 2/9/2016 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | N/A | View details for Dawson James rating of Enzo Biochem (NYSE:ENZ) on 2/9/2016 |
SLNO Soleno Therapeutics | $47.48
+1.9% | 5/6/2015 | Initiated by | Dawson James | - | Buy | $952.50 | N/A | View details for Dawson James rating of Soleno Therapeutics (NASDAQ:SLNO) on 5/6/2015 |
CVM CEL-SCI | $2.83
-1.0% | 3/2/2015 | Initiated by | Dawson James | - | Buy | $3.00 | N/A | View details for Dawson James rating of CEL-SCI (NYSE:CVM) on 3/2/2015 |
AXGN AxoGen | $9.87
+1.9% | 5/14/2014 | Initiated by | Dawson James | - | Buy | $5.00 | N/A | View details for Dawson James rating of AxoGen (NASDAQ:AXGN) on 5/14/2014 |
NEO NeoGenomics | $14.50
+3.2% | 5/14/2014 | Initiated by | Dawson James | - | Buy | $6.00 | N/A | View details for Dawson James rating of NeoGenomics (NASDAQ:NEO) on 5/14/2014 |
ABIO ARCA biopharma | $1.65
+3.1% | 10/9/2013 | Initiated by | Dawson James | - | Buy | $3.75 | N/A | View details for Dawson James rating of ARCA biopharma (NASDAQ:ABIO) on 10/9/2013 |
AGEN Agenus | $0.70
+3.0% | 3/12/2013 | Reiterated by | Dawson James | - | Buy | | N/A | View details for Dawson James rating of Agenus (NASDAQ:AGEN) on 3/12/2013 |
MD Pediatrix Medical Group | $8.99
+1.1% | 3/12/2013 | Downgraded by | Dawson James | - | Buy -> Neutral | $80.00 | N/A | View details for Dawson James rating of Pediatrix Medical Group (NYSE:MD) on 3/12/2013 |
ARWR Arrowhead Pharmaceuticals | $30.85
-2.5% | 2/26/2013 | Initiated by | Dawson James | - | Buy | $4.00 | N/A | View details for Dawson James rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 2/26/2013 |
ATOS Atossa Therapeutics | $0.94
-1.1% | 12/20/2012 | Initiated by | Dawson James | - | Outperform | $120.00 | N/A | View details for Dawson James rating of Atossa Therapeutics (NASDAQ:ATOS) on 12/20/2012 |
BMY Bristol-Myers Squibb | $48.71
+0.1% | 12/12/2012 | Reiterated by | Dawson James | - | Market Outperform | $51.00 | N/A | View details for Dawson James rating of Bristol-Myers Squibb (NYSE:BMY) on 12/12/2012 |
AMGN Amgen | $294.85
-0.3% | 12/7/2012 | Initiated by | Dawson James | - | Outperform | $91.00 | N/A | View details for Dawson James rating of Amgen (NASDAQ:AMGN) on 12/7/2012 |
GEO The GEO Group | $12.02
+5.0% | 12/4/2012 | Downgraded by | Dawson James | - | Market Perform | | N/A | View details for Dawson James rating of The GEO Group (NYSE:GEO) on 12/4/2012 |
SRPT Sarepta Therapeutics | $127.38
+1.1% | 11/27/2012 | Initiated by | Dawson James | - | Outperform | | N/A | View details for Dawson James rating of Sarepta Therapeutics (NASDAQ:SRPT) on 11/27/2012 |
RMTI Rockwell Medical | $1.23
-1.6% | 11/27/2012 | Initiated by | Dawson James | - | Outperform | $132.00 | N/A | View details for Dawson James rating of Rockwell Medical (NASDAQ:RMTI) on 11/27/2012 |
AGEN Agenus | $0.70
+3.0% | 11/27/2012 | Initiated by | Dawson James | - | Outperform | | N/A | View details for Dawson James rating of Agenus (NASDAQ:AGEN) on 11/27/2012 |
SLS SELLAS Life Sciences Group | $0.78
+6.9% | 11/27/2012 | Initiated by | Dawson James | - | Outperform | $150.00 | N/A | View details for Dawson James rating of SELLAS Life Sciences Group (NASDAQ:SLS) on 11/27/2012 |
CYTK Cytokinetics | $78.94
+2.4% | 11/27/2012 | Downgraded by | Dawson James | - | Outperform | | N/A | View details for Dawson James rating of Cytokinetics (NASDAQ:CYTK) on 11/27/2012 |
GALT Galectin Therapeutics | $1.63
+1.9% | 7/6/2012 | Target Lowered by | Dawson James | - | Buy | $3.00 | N/A | View details for Dawson James rating of Galectin Therapeutics (NASDAQ:GALT) on 7/6/2012 |
NFLX Netflix | $558.53
-0.1% | 10/28/2011 | Target Lowered by | Dawson James | - | Sell | $16.50 -> $7.14 | N/A | View details for Dawson James rating of Netflix (NASDAQ:NFLX) on 10/28/2011 |
